Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 12, 2017, Pages 2918-2930

  Maslow, Joel N ^a  

^a GeneOne Life Science Inc   (South Korea)

Author keywords

Coronavirus; DNA vaccine; Emerging infectious disease; Epidemic; Epidemiology; Flavivirus; MERS CoV; Vaccine; Zika virus

Indexed keywords

DIPEPTIDYL PEPTIDASE; DNA VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; VITRONECTIN; ZIKA VIRUS VACCINE; VIRUS VACCINE;

ACUTE KIDNEY FAILURE; ARTHRALGIA; ARTICLE; BETACORONAVIRUS; CLINICAL TRIAL (TOPIC); DETERIORATION; HEADACHE; HEART ARRHYTHMIA; HUMAN; IMMUNOGENICITY; IMMUNOLOGY; LUNG INFECTION; MICROCEPHALY; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MYALGIA; NONHUMAN; SEXUAL TRANSMISSION; SORE THROAT; VIRUS INFECTION; ZIKA FEVER; ZIKA VIRUS; COMMUNICABLE DISEASE; CORONAVIRUS INFECTION; DRUG DEVELOPMENT; ISOLATION AND PURIFICATION; ORGANIZATION AND MANAGEMENT; PROCEDURES;

COMMUNICABLE DISEASES, EMERGING; CORONAVIRUS INFECTIONS; DRUG DISCOVERY; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; VIRAL VACCINES; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85033701462     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2017.1358325     Document Type: Article

References (158)

1. Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, van Boheemen S, Gopal R, Ballhause M, Bestebroer TM, et al. Detection of a novel human coronavirus by real-time reversetranscription polymerase chain reaction. Euro Surveill. 2012;17(39):20285. doi:10.1056/NEJMoa1211721.
2. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814-20.
3. Centers for Disease Control and Prevention (CDC). Update: Severe respiratory illness associated with Middle East Respiratory Syndrome coronavirus (MERS-CoV) - worldwide, 2012-2013. MMWR Morb Mortal Wkly Rep. 2013;62(23):480-3. doi:10.7326/M13-2486.
4. Arabi Y, Arifi A, Balkhy H, Najm H, Aldawood A, Ghabashi A, Hawa H, Alothman A, Khaldi A, Al Raiy B. Clinical course and outcomes of critically ill patients with Middle East Respiratory Syndrome coronavirus infection. Ann Intern Med. 2014;160:389-97.
5. Guery B, Poissy J, el Mansouf L, Séjourné C, Ettahar N, Lemaire X, Vuotto F, Goffard A, Behillil S, Enouf V, et al. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: A report of nosocomial transmission. Lancet. 2013;381(9885):2265-72. doi:10.1016/S0140-6736(13)60982-4.
6. Assiri A, McGeer A, Perl TM, Price CS, Al-Rabeeah AA, Cummings DAT, Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H, et al. Hospital outbreak of Middle East Respiratory Syndrome coronavirus. N Engl J Med. 2013;369(5):407-16. doi:10.1056/ NEJMoa1306742.
7. Harriman K, Brosseau L, Trivedi K. Hospital-associated Middle East Respiratory Syndrome coronavirus infections. N Engl J Med. 2013;369(18):1761-2. doi:10.1056/NEJMc1311004.
8. Kim KM, Ki M, Cho SI, Sung M, Hong JK, Cheong HK, Kim JH, Lee SE, Lee C, Lee KJ, et al. Epidemiologic features of the first MERS outbreak in Korea: Focus on Pyeongtaek St. Mary’s Hospital. Epidemiol Health. 2015;37:e2015401. doi:10.4178/epih/e2015041.
9. Oh M-d, Choe PG, Oh HS, Park WB, Lee M-S, Park J, Lee SK, Song JS, Kim NJ. Middle East respiratory syndrome coronavirus superspreading event involving 81 persons, Korea 2015. J Korean Med Sci. 2015;30:1701-5. doi:10.3346/jkms.2015.30.11.1701.
10. Assiri A, Abedi GR, Saeed AA, Abdalla MA, Al-Masry M, Choudhry AJ, Lu X, Erdman DD, Tatti K, Binder AM, et al. Multifacility outbreak of Middle East Respiratory Syndrome in Taif, Saudi Arabia. Emerg Infect Dis. 2016;22(1):32-40. doi:10.3201/ eid2201.151370.
11. Drosten C, Meyer B, Muller MA, Corman VM, Al-Masri M, Hossain R, Madani H, Sieberg A, Bosch BJ, Lattwein E, et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med. 2014;371:828-35. doi:10.1056/NEJMoa1405858.
12. Farag EA, Reusken CB, Haagmans BL, Mohran KA, Stalin Raj V, Pas SD, Voermans J, Smits SL, Godeke GJ, Al-Hajri MM, et al. High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014. Infect Ecol Epidemiol. 2015;5:28305. doi:10.3402/iee. v5.28305.
13. Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM, Madani TA. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med. 2014;370(26):2499-505. doi:10.1056/NEJMoa1401505.
14. Drosten C, Kellam P, Memish ZA. Evidence of camel-to-human transmission of MERS coronavirus. N Engl J Med. 2014;371(14):1359-60. doi:10.1056/NEJMc1409847.
15. Hemida MG, Elmoslemany A, Al-Hizab F, Alnaeem A, Almathen F, Faye B, Chu DK, Perera RA, Peiris M. Dromedary camels and the transmission of Middle East Respiratory Syndrome coronavirus (MERS-CoV). Transbound Emerg Dis. 2017;64(2):344-53. doi:10.1111/tbed.12401.
16. Cotten M, Watson SJ, Zumla A, Makhdoom HQ, Palser AL, Ong SH, Al Rabeeah AA, Alhakeem RF, Assiri A, Al-Tawfiq JA, et al. Spread, circulation, and evolution of the Middle East Respiratory Syndrome coronavirus. MBio. 2014;5(1):e01062-13. doi:10.1128/ mBio.01062-13.
17. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) - Thailand. Geneva, (SW): World Health Organization; 2016 [accessed 2016 Jan 30]. http://www.who.int/csr/ don/29-january-2016-mers-thailand/en/
18. Lee S. Costly lessons from the 2015 Middle East respiratory syndrome coronavirus outbreak in Korea. J Prev Med Public Health. 2015;48:274-6. doi:10.3961/jpmph.15.064.
19. van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, Osterhaus AD, Haagmans BL, Gorbalenya AE, Snijder EJ, et al. Geonomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio. 2012;3(6):e00473-12. doi:10.1128/mBio.00473-12.
20. Memish ZA, Mishra N, Olival KJ, Fagbo SF, Kapoor V, Epstein JH, Alhakeem R, Durosinloun A, Al Asmari M, Islam A, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis. 2013;19(11):1819-23. doi:10.3201/eid1911.131172.
21. Raj VS, Mou H, Smits SL, Dekkers DH, Müller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251-4. doi:10.1038/nature12005.
22. Wang Q, Qi J, Yuan Y, Xuan Y, Han P, Wan Y, Ji W, Li Y, Wu Y, Wang J, et al. Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host Microbe. 2014;16(3):328-37. doi:10.1016/j.chom.2014.08.009.
23. Yang Y, Du L, Liu CB, Wang L, Ma C, Tang J, Baric RS, Jiang S, Li F. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc Natl Acad Sci U S A. 2014;111(34):12516-21. doi:10.1073/ pnas.1405889111.
24. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, et al. Angiotensin- converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(69655):450-4. doi:10.1038/ nature02145.
25. Barlan A, Zhao J, Sarkar MK, Li K, McCray PB Jr, Perlman S, Gallagher T. Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection. J Virol. 2014;88(9):4953-61. doi:10.1128/JVI.00161-14.
26. van Doremalen N, Miazgowicz KL, Milne-Price S, Bushmaker T, Robertson S, Scott D, Kinne J, McLellan JS, Zhu J, Munster VJ. Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. J Virol. 2014;88(16):9220-32. doi:10.1128/JVI.00676-14.
27. Hemida MG, Chu DK, Poon LL, Perera RA, Alhammadi MA, Ng HY, Siu LY, Guan Y, Alnaeem A, Peiris M. MERS coronavirus in dromedary camel herd, Saudi Arabia. Emerg Infect Dis. 2014;20(7):1231-4. doi:10.3201/eid2007.140571.
28. Meyer B, Muller MA, Corman VM, Reusken CB, Ritz D, Godeke GJ, Lattwein E, Kallies S, Siemens A, van Beek J, et al. Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. Emerg Infect Dis. 2014;20(4):552-9. doi:10.3201/eid2004.131746.
29. Woo PC, Lau SK, Wernery U, Wong EY, Tsang AK, Johnson B, Yip CC, Lau CC, Sivakumar S, Cai JP, et al. Novel betacoronavirus in dromedaries of the Middle East, 2013. Emerg Infect Dis. 2014;20(4):560-72. doi:10.3201/eid2004.131769.
30. Yusof MF, Eltahir YM, Serhan WS, Hashem FM, Elsayed EA, Marzoug BA, Abdelazim AS, Bensalah OK, Al Muhairi SS. Prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Abu Dhabi Emirate, United Arab Emirates. Virus Genes. 2015;50(3):509-13. doi:10.1007/s11262-015-1174-0.
31. Reusken CB, Messadi L, Feyisa A, Ularamu H, Godeke GJ, Danmarwa A, Dawo F, Jemli M, Melaku S, Shamaki D, et al. Geographic distribution of MERS coronavirus among dromedary camels, Africa. Emerg Infect Dis. 2014;20(8):1370-4. doi:10.3201/ eid2008.140590.
32. Adney DR, van Doremalen N, Brown VR, Bushmaker T, Scott D, de Wit E, Bowen RA, Munster VJ. Replication and shedding of MERSCoV in upper respiratory tract of inoculated dromedary camels. Emerg Infect Dis. 2014;20(12):1999-2005. doi:10.3201/ eid2012.141280.
33. Reusken CB. Infection of Alpaca in a region where MERS-CoV is endemic. Emerg Infect Dis. 2016;22(6):1129-31. doi:10.3201/ eid2206.152113.
34. Wang LF, Eaton BT. Bats, civets and the emergence of SARS. Curr Top Microbiol Immunol. 2007;315:325-44. doi:10.1016/j. antiviral.2015.07.005.
35. van Doremalen N, Munster VJ. Animal models of Middle East respiratory syndrome coronavirus infection. Antiviral Res. 2015;122:28-38.
36. Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villareal DO, Wise M, Patel A, Izmirly A, Aljuaid A, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med. 2015;7(301):301ra132. doi:10.1126/scitranslmed.aac7462.
37. Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015;6:7712. doi:10.1038/ncomms8712.
38. Falzarano D, de Wit E, Feldmann F, Rasmussen AL, Okumura A, Peng X, Thomas MJ, van Doremalen N, Haddock E, Nagy L, et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 2014;10(8):e1004250. doi:10.1371/journal. ppat.1004250.
39. Johnson RF, Via LE, Kumar MR, Cornish JP, Yellayi S, Huzella L, Postnikova E, Oberlander N, Bartos C, Ork BL, et al. Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease. Virology. 2015;485:422-30. doi:10.1016/j.virol.2015.07.013.
40. Agrawal AS, Garron T, Tao X, Peng BH, Wakamiya M, Chan TS, Couch RB, Tseng CT. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol. 2015;89(7):3659-70. doi:10.1128/JVI.03427-14.
41. Tao X, Garron T, Agrawal AS, Algaissi A, Peng BH, Wakamiya M, Chan TS, Lu L, Du L, Jiang S, et al. Characterization and demonstration of the value of a lethal mouse model of Middle East Respiratory Syndrome coronavirus infection and disease. J Virol. 2015;90(1):57-67. doi:10.1128/JVI.02009-15.
42. Zhao G, Jiang Y, Qiu H, Gao T, Zeng Y, Guo Y, Yu H, Li J, Kou Z, Du L, et al. Multi-organ damage in human dipeptidyl peptidase 4 transgenic mice infected with Middle East respiratory syndrome coronavirus. PLoS One. 2015;10(12):e0145561. doi:10.1371/journal. pone.0145561.
43. Pascal KE, Coleman CM, Mujica AO, Kamat V, Badithe A, Fairhurst J, Hunt C, Strein J, Berrebi A, Sisk JM, et al. Pre- and postexposure efficacy of fully immunized antibodies against spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2015;112(28):8738-43. doi:10.1073/ pnas.1510830112.
44. Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fetta C, Zhao J, Gale MJ, Baric RS, Enjuanes L, Gallagher T, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. PNAS. 2014;111:5
45. Crameri G, Durr PA, Klein R, Foord A, Yu M, Riddell S, Haining J, Johnson D, Hemida MG, Barr J, et al. Experimental infection and response to rechallenge of alpacas with Middle East Respiratory Syndrome coronavirus. Emerg Infect Dis. 2016;22(6):1071-3. doi:10.3201/eid2206.160007.
46. Feiken DR, Alraddadi B, Qutub M, Shabouni O, Curns A, Oboho IK, Tomczyk SM, Wolff B, Watson JT, Madani TA. Association of higher MERS-CoV virus load with severe disease and death, Saudi Arabia, 2014. Emerg Infect Dis. 2015;21(11):2029-35. doi:10.3201/ eid2111.150764.
47. Kim SY, Park SJ, Cho SY, Cha R-h, Jee H-G, Kim G, Shin HS, Kim Y, Jung YM, Yang JS, et al. Viral RNA in blood as indicator of severe outcome in Middle East Respiratory Syndrome coronavirus infection. Emerg Infect Dis. 2016;22(10):1813-6. doi:10.3201/ eid2210.160218.
48. Corman VM, Albarrak AM, Omrani AS, Albarrak MM, Farah ME, Almasri M, Muth D, Sieberg A, Meyer B, Assiri AM, et al. Viral shedding and antibody response in 37 patients with Middle East Respiratory Syndrome coronavirus Iinfection. Clin Infect Dis. 2016;62(4):477-83. doi:10.1093/cid/civ951.
49. Tang F, Quan Y, Xin ZT, Wrammert J, Ma MJ, Lv H, Wang TB, Yang H, Richardus JH, Liu W, et al. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: A six-year follow-up study. J Immunol. 2011;186(12):7264-8. doi:10.4049/jimmunol.0903490.
50. Wu LP, Wang NC, Chang YH, Tian XY, Na DY, Zhang LY, Zheng L, Lan T, Wang LF, Liang GD. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562-4. doi:10.3201/eid1310.070576.
51. Channappanavar R, Fett C, Zhao J, Meyerholz DK, Perlman S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol. 2014;88(19):11034-44. doi:10.1128/JVI.01505-14.
52. Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010;84(18):9318-25. doi:10.1128/JVI.01049-10.
53. Park WB, Perera RA, Choe PG, Lau EHY, Choi SJ, Chun JY, Oh HS, Song KH, Bang JH, Kim ES, et al. Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea. Emerg Infect Dis. 2015;21(12):2186-9. doi:10.3201/eid2112.151421.
54. Payne DC, Iblan I, Rha B, Alqasrawi S, Haddadin A, Al NsourM, Alsanouri T, Ali SS, Harcourt J, Miao C, et al. Persistence of antibodies againstMiddle East Resporatory coronavirus. Emerg Infect Dis. 2016;22(10):1824-6. doi:10.3201/eid2210.160706.
55. Hemida MG, Al-Naeem A, Perera RA, Chin AW, Poon LL, Peiris M. Lack of middle East respiratory syndrome coronavirus transmission from infected camels. Emerg Infect Dis. 2015;21(4):699-701. doi:10.3201/eid2104.141949.
56. Memish ZA, Alsahly A, Masri MA, Heil GL, Anderson BD, Peiris M, Khan SU, Gray GC. Sparse evidence of MERS-CoV infection among animal workers living in Southern Saudi Arabia during 2012. Influenza Other Respir Viruses. 2015;9(2):64-67. doi:10.1111/ irv.12287.
57. Excler JL, Delvecchio CJ, Wiley RE, Williams M, Yoon I-K, Modjarrad K, Boujelal M, Moorthy VS, Hersi AS, Kim JH. Toward developing a preventive MERS-CoV vaccine-report from a workshop organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015. Emerg Infect Dis. 2016;22(8):e1-e7. doi:10.3201/eid2208.160229.
58. Modjarrad K, Moorthy VS, Ben Embarek P, Van Kerkhove M, Kim JA, Kieny MP. A roadmap for MERS-CoV research and product development: Report from a World Health Organization consultation. Nat Med. 2016;22(7):701-5. doi:10.1038/nm.4131.
59. Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, AlHajri F, Osterhaus AD, Haagmans BL, Gambotto A. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. Vaccine. 2014;32(45):5975-82. doi:10.1016/j.vaccine.2014.08.058.
60. Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H, Schmidt J, Becker C, Eickmann M, Becker S, et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East Respiratory Syndrome coronavirus spike glycoprotein. J Virol. 2015;89(16):8651-6. doi:10.1128/JVI.00614-15.
61. Malczyk AH, Kupke A, Prufer S, Scheuplein VA, Hutzler S, Kreuz D, Beissert T, Bauer S, Hubich-Rau S, Tondera C, et al. A highly immunogenic and protective Middle East Respiratory Syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J Virol. 2015;89(22):11654-67. doi:10.1128/JVI.01815-15.
62. Lan J, Deng Y, Chen H, Lu G,WangW, Guo X, Lu Z, Gao GF, TanW. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERSCoV) receptor-binding domain as an antigen. PLoS One. 2014;9(11):e112602. doi:10.1371/journal.pone.0112602.
63. Zhang N, Tang J, Lu L, Jiang S, Du L. Receptor-binding domainbased subunit vaccines against MERS-CoV. Virus Res. 2015;202:151-9. doi:10.1016/j.virusres.2014.11.013.
64. Du L, TaiW, Yang Y, Zhao G, Zhu Q, Sun S, Liu C, Tao X, Tseng CK, Perlman S, et al. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus vaccines. Nat Commun. 2016;7:13473. doi:10.1038/ncomms13473.
65. Coleman CM, Liu YV, Mu H, Taylor JK, Massare M, Flyer DC, Smith GE, Frieman MB. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine. 2014;32(26):3169-74. doi:10.1016/j.vaccine.2014.04.016.
66. Coleman CM, Venkatraman N, Liu T, Glenn YV, Smith GE, Flyer DC, Frieman MB. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine. 2017;35(12):1586-9. doi:10.1016/j.vaccine.2017.02.012.
67. Chi H, Zheng X, Wang X, Wang C, Wang H, Gai W, Perlman S, Yang S, Zhao J, Xia X. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. Vaccine. 2017;35:2069-75. doi:10.1016/j. vaccine.2017.02.063.
68. Al-amri SS, Abbas AT, Siddiq LA, Alghamdi A, Sanki MA, Al-Muhanna MK, Albabbab RY, Axhar EI, Li X, Hashem AM. Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein. Sci Rep. 2016;7:44875. doi:10.1038/srep44875
69. Henao-Restrepo AM, Camacho A, Longini IM,Watson CH, Edmunds WJ, Egger M, CarrollMW, Dean NE, Diatta I, Doumbia M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2017;389(10068):505-18. doi:10.1016/ S0140-6736(16)32621-6.
70. Majumder MS, Kluberg SA, Mekaru SR, Brownstein JS. Mortality risk factors for Middle East respiratory syndrome outbreak, South Korea, 2015. Emerg Infect Dis. 2015;21(11):2088-90. doi:10.3201/ eid2111.151231.
71. Fagbami AH. Zika virus infection in Nigeria: Virological and seroepidemiological investigations in Oyo State. J Hyg (Lond). 1979;83:213-9. doi:10.1017/S0022172400025997.
72. Geser A, Henderson BE, Christensen S. A multipurpose serological survey in Kenya. 2. Results of arbovirus serological tests. Bull World Health Organ. 1970;43:539-52. doi:10.1056/NEJMoa0805715.
73. Renaudet J, Ridet C, Ridet J, Adam C, Robin Y. Enquete serologique pour les arbovirus dans la population humaine du Senegal. Bull Soc Pathol Exot Filiales. 1978;71:131-40.
74. Smithburn KC. Neutralizing antibodies against certain recently isolated viruses in the sera of human beings residing in East Africa. J Immunol. 1952;69:223-34.
75. Duffy MR, Chen T-H, Hancock WT, Powers AM, Kool JL, Lanciotti RS, Pretrick M, Marfel M, Holzbauer S, Dubray C, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360(24):2536-43.
76. Cao-Lormeau VM, Roche C, Teissier A, Robin E, Berry A-L, Mallet HP, Sall AA, Musso D. Zika virus, French Polynesia, South Pacific, 2013. Emerg Infect Dis. 2014;20(6):1086-7. doi:10.3201/eid2006.140138
77. European Centre for Disease Prevention and Control. Rapid risk assessment: Zika virus infection outbreak, French Polynesia, 14 February 2014. In. Stockholm: ECDC; 2014
78. Musso D, Nilles EJ, Cao-Lormeau VM. Rapid spread of emerging Zika virus in the Pacific area. Clin Microbiol Infect. 2014;20(10):O595-6. doi:10.1111/1469-0691.12707.
79. Campos GS, Bandeira AC, Sardi SI. Zika virus outbreak, Bahia Brazil. Emerg Infect Dis. 2015;21(10):1885-6. doi:10.3201/eid2110.150847.
80. Cardoso CW, Paploski IAD, Kikuti M, Rodrigues MS, Silva MMO, Campos GS, Sardi SI, Kitron U, Reis MG, Ribeiro GS. Outbreak of exanthematous illness associaetd with Zika, chikungunya, and dengue viruses, Salvador, Brazil. Emerg Infect Dis. 2015;22(12):2274-6. doi:10.3201/eid2112.151167
81. Crowe K. Microcephaly cases in Brazil predate Zika virus outbreak, study says. CBC News, Toronto [CA]: CBC Radio-Canada; 2016. http://www.cbc.ca/news/health/microcephaly-brazil-zika-reality-1.3442580 [accessed 2016 Sep 14].
82. Diallo D, Sall AA, Diagne CT, Faye O, Faye O, Ba Y, Hanley KA, Buenemann M, Weaver SC, Diallo M. Zika virus emergence in mosquitoes in Southeastern Senegal, 2011. PLoS One. 2011;9(10):e109442. doi:10.1371/journal.pone.0109442
83. Haddow AJ, Williams MC, Woodall JP, Simpson DIH, Goma LKH. Twelve isolations of Zika virus from Aedes (Stegomyia) africanus (Theobald) taken in and above a Ugandan forest. Bull World Health Organ. 1964;31:57-69. doi:10.1371/journal. pntd.0003188.
84. Ledermann JP, Guillamot L, Yug L, Saweyog SC, Tided M, Machieng P, Pretrick M, Marfel M, Griggs A, Bel M, et al. Aedes hensilli as a potential vector of chikungunya and Zika viruses. PLoS Negl Trop Dis. 2014;8(10):e3188.
85. Marchette NJ, Garcia R, Rudnik A. Isolation of Zika virus from Aedes aegypti mosquitoes in Malaysia. Am J Trop Med Hyg. 1969;18(3):411-5. doi:10.4269/ajtmh.1969.18.411.
86. Aliota MT, Peinado SA, Osorio JE, Bartholomay LC. Culex pipiens and Aedes triseriatus mosquito susceptibility to Zika virus. Emerg Infect Dis. 2016;22(10):1857-9. doi:10.3201/ eid2210.161082.
87. Chouin-Carneiro T, Vega-Rua A, Vazeille M, Yebakima A, Girod R, Goindin D, Dupont-Rouzeyrol M, Lourenço-de-Oliveira R, Failloux AB. Differential susceptibilities of Aedes aegypti and Aedes albopticus from the Americas to Zika virus. PLoS Negl Trop Dis. 2016;10(3):e0004543. doi:10.1371/journal. pntd.0004543.
88. Thangamani S, Huang J, Hart CE, Guzman H, Tesh RB. Vertical transmission of Zika virus in mosquitoes. Am J Trop Med Hyg. 2016;95(5):1169-73. doi:10.4269/ajtmh.16-0448.
89. Atkinson B, Hearn P, Afrough B, Lumley S, Carter D, Aarons EJ, Simpson AJ, Brooks TJ, Hewson R. Zika virus in semen. Emerg Infect Dis. 2016;22(6):940. doi:10.3201/eid2205.160107.
90. Brooks RB, Carlos MP, Myers RA, White MG, Bobo-Lenoci T, Aplan D, Blythe D, Feldman KA. Likely sexual transmission of Zika virus from a man with no symptoms of infection, Maryland, 2016. MMWR 2016;65(34):915-6. doi:10.15585/mmwr.mm6534e2.
91. Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau VM. Potential sexual transmission of Zika virus. Emerg Infect Dis. 2015;21(2):359-61. doi:10.3201/eid2102.141363.
92. BesnardM, Lastere S, TeissierA, Cao-Lormeau VM,MussoD. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. Euro Surveill. 2014;19(13):20751. doi:10.2807/1560-7917.ES2014.19.13.20751.
93. Musso D, Roche C, Nhan TX, Robin E, Teissier A, Cao-Lormeau VM. Detection of Zika virus in saliva. J Clin Virol. 2015;68:53-55. doi:10.1016/j.jcv.2015.04.021.
94. Focosi D, Maggi F, Pistello M. Zika virus: Implications for public health. Clin Infect Dis. 2016;63(2):227-33. doi:10.1093/cid/ciw210.
95. Bell TM, Field RJ, Narang HK. Zika virus infection of the central nervous system of mice. Arch Gesamte Virusforsch. 1971;35(2):183-93. doi:10.1007/BF01249709.
96. Cao-LormeauVM, BlakeA,Mons S, Lastere S, Roche C,Vanhomwegen J, Dub T, Baudouin L, Teissier A, Larre P, et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: A case-control study. Lancet. 2016;387(10027):1531-9. doi:10.1016/S0140-6736(16)00562-6.
97. Carteaux G, Maquart M, Bedet A, Contou D, Brugières P, Fourati S, Cleret de Langavant L, de Broucker T, Brun-Buisson C, Leparc-Goffart I, et al. Zika virus associated with meningoencephalitis. N Engl J Med. 2016;374(16):1595-6. doi:10.1056/NEJMc1602964.
98. Pan Am Health Organization. Epidemiological alert. Neurological syndrome, congenital malformations, and Zika virus infection. Implications for public health in the Americas. 1 December 2015. In. Washington (DC): World Health Organization, Pan American Health Organization; 2015
99. Ministério da Saude (Brazil). Ministério da Saúde investiga aumento de casos de microcefalia em Pernambuco. Brasilia [BR]:Ministério da Saude (Brazil); 2015 [accessed 2016 Jan 30]. http:// portalsaude.saude.gov.br/index.php/cidadao/principal/agenciasaude/20629-ministerio-da-saude-investiga-aumento-de-casos-demicrocefalia- em-pernambuco
100. Besnard M, Eyrolle-Guignot D, Guillamette-Artur P, Lastere S, Bost-Bezeaud F, Marcellis L, Abadie V, Garel C, Moutard ML, Jouannic JM, et al. Congenital cerebral malformations and dysfunction in fetuses and newborns following the 2013 to 2014 Zika virus epidemic in French Polynesia. Euro Surveill. 2016;21(13):22-30. piiD 30181. doi:10.2807/1560-7917.ES.2016.21.13.30181.
101. Nishiura H, Mizumoto K, Rock KS, Yasuda Y, Kinoshita R, Miyamatsu Y. A theoretical estimate of the risk of microcephaly during pregnancy with Zika virus infection. Epidemics. 2016;15:66-70. doi:10.1016/j.epidem.2016.03.001.
102. Brasil P, Pereira JP, Moreira ME, Nogueira RMR, Damasceno L, Wakimoto M, Rabello RS, Valderramos SG, Halai UA, Salles TS, et al. Zika virus infection in pregnant women in Rio de Janeiro. N Engl J Med. 2016;375(24):2321-22334. doi:10.1056/ NEJMoa1602412.
103. European Centre for Disease Prevention and Control. Rapid risk assessment. ZIka virus epidemic in the Americas: potential association with microcephalyh and Guillain-Barreé syndrome. Solna [SW]: ECDC; 2015 [accessed 2016 Jan 30]. https://ecdc.europa.eu/ sites/portal/files/media/en/publications/Publications/zika-virusamericas- association-with-microcephaly-rapid-risk-assessment.pdf.
104. Leal MC, Muniz LF, Ferreira TSA, Santos CM, Almeida LC, Van Der Linden V, Ramos RC, Rodrigues LC, Neto SS. Hearing loss in infants with microcephaly and evidence of congenital Zika virus infection - Brazil, November 2015 - May 2016. MMWR Morb Mortal Wkly Rep. 2016;65(34):917-9. doi:10.15585/mmwr.mm6534e3.
105. Adams Waldorf KM, Stencel-Baerenwald JE, Kapur RP, Studholme C, Boldenow E, Vornhagen J, Baldessari A, Dighe MK, Thiel J, Merillat S, et al. Fetal brain lesions after subcutaneous inoculation of Zika virus in a pregnant nonhuman primate. Nat Med. 2016;22(11):1256-9. doi:10.1038/nm.4193.
106. Meaney-Delman D, Oduyebo T, Polen KND, White JL, Bingham AM, Slavinski SA, Heberlein-Larson L, St George K, Rakeman JL, Hills S, et al. Prolonged detection of Zika virus RNA in pregnant women. Obstet Gynecol. 2016;128(4):724-30. doi:10.1097/ AOG.0000000000001625.
107. Oliveira DBL, Almeida FJ, Durigon EL, Mendes EA, Braconi CT, Marchetti I, Andreata-Santos R, Cunha MP, Alves RP, Pereira LR, et al. Prolonged shedding of Zika virus associated with congenital infection. N Engl J Med. 2016;375(12):1202-4. doi:10.1056/ NEJMc1607583.
108. Sun LH. Miscarriages reported in 2 U.S. women with Zika virus, CDC says. In: phillycom. Washington (DC): Washington Post; 2016
109. Govero J, Esakky P, Scheaffer SM, Fernandez E, Drury A, Platt DJ, Gorman MJ, Richner JM, Caine EA, Salazar V, et al. Zika virus infection damages the testes in mice. Nature. 2016;540(15 December):438-42. doi:10.1038/nature20556.
110. HuzlyD,Hanselmann I, Schmidt-Chansit J, Panning M. High specificity of a novel Zika virus ELISA in European patients after exposure to different flaviviruses. Euro Surveill. 2016;21(16):pii D 30203. doi:10.2807/1560-7917.ES.2016.21.16.30203.
111. Bingham AM, Cone M, Mock V, Heberlein-Larson L, Stanek D, Blackmore C, Likos A. Comparison of test results for Zika virus RNA in urine, serum, and saliva specimens from persons with travel-associated Zika virus disease - Florida, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(18):475-8. doi:10.15585/mmwr. mm6518e2.
112. Shukla S, Hong SY, Chung SH, Kim MG. Rapid detection strategies for the global threat of Zika virus: Current state, new hypotheses, and limitations. Front Microbiol. 2016;7:1685. doi:10.3389/ fmicb.2016.01685.
113. Jeong YE, Cha GW, Cho JE, Lee EJ, Lee WJ. Viral and serologic kinetics in Zika virus-infected patients in South Korea. Virol J. 2017;14:70. doi:10.1186/s12985-017-0740-6.
114. Gourinat A-C, O’Connor O, Calvez E, Goarant C, Dupont-Rouzeyrol M. Detection of Zika virus in urine. Emerg Infect Dis. 2015;21(1):84-86. doi:10.3201/eid2101.140894.
115. Patino-Barbosa AM, Medina I, Gil-Restrepo AF, Rodriguez-Morales AJ. Zika: Another sexually transmitted infection? Sex Transm Infect. 2015;91(5):359. doi:10.1136/sextrans-2015-052189.
116. Fourcade C, Mansuy J-M, Dutertre M, Delpech M, Marchou B, Delobel P, Izopet J, Martin-Blondel G. Viral load kinetics of Zika virus in plasma, urine and saliva in a couple returning from Martinique, French West Indies. J Clin Virol. 2016;82:1-4. doi:10.1016/j. jcv.2016.06.011.
117. Bowen JR, Quicke KM, Maddur MS, O’Neal JT, McDonald CE, Fedorova NB, Puri V, Shabman RS, Pulendran B, Suthar MS. Zika virus antagonizes Type I interferon responses during infection of human dendritic cells. PLoS Pathog. 2017;13(2):e1006164. doi:10.1371/journal.ppat.1006164.
118. Grant A, Ponia SS, Tripathi S, Balasubramaniam V, Miorin L, Sourisseau M, Schwarz MC, Sánchez-Seco MP, Evans MJ, Best SM, et al. Zika virus targets human STAT2 to inhibit Type I interferon signaling. Cell Host Microbe. 2016;19(6):882-90. doi:10.1016/j. chom.2016.05.009.
119. Winkler CW,Myers LM,Woods TA,Messer RJ, CarmodyAB,McNally KL, ScottDP, Hasenkrug KJ, Best SM, Peterson KE. Adaptive immune responses to Zika virus are important for controlling virus infection and preventing infection in brain and testes. J Immunol. 2017;198:3526-35. doi:10.4049/jimmunol.1601949.
120. Aid M, Abbink P, Larocca RA, Boyd M, Nityanandam R, Nanayakkara O, Martinot AJ, Moseley ET, Blass E, Borducchi EN, et al. Zika virus persistence in the central nervous system and lymph nodes of rhesus monkeys. Cell. 2017;169:610-20. doi:10.1016/j. cell.2017.04.008.
121. Liang Q, Luo Z, Zeng J, Chen W, Foo SS, Lee SA, Ge J, Wang S, Goldman SA, Zlokovic BV. Zika virus NS4A and NS4B proteins deregulate Akt-mTOR signaling in human fetal neural stem cells to inhibit neurogenesis and induce autophagy. Cell Stem Cell. 2016;19:1-9. doi:10.1016/j.stem.2016.07.019.
122. Anderson KB, Gibbons RV, Cummings DAT, Nisalak A, Green S, Libraty DH, Jarman RG, Srikiatkhachorn A, Mammen MP, Darunee B, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort from Thailand. J Infect Dis. 2014;209(1 February):360-8. doi:10.1093/infdis/jit436.
123. Halstead SB, O’Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med. 1977;146:201-17. doi:10.1084/jem.146.1.201.
124. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg. 1989;40(4):444-51. doi:10.4269/ajtmh.1989.40.444.
125. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, Rothman AL, Libraty DH. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis. 2004;189(6):990-1000. doi:10.1086/382280.
126. Laoprasopwattana K, Libraty DH, Endy TP, Nisalak A, Chunsuttiwat S, Vaughn DW, Reed G, Ennis FA, Rothman AL, Green S. Dengue virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis. 2005;192(3):510-9. doi:10.1086/431520.
127. Henderson BE, Cheshire PP, Kirya GB, Lule M. Immunologic studies with yellow fever and selected African Group B arboviruses in rhesus and vervet monkeys. Am J Trop Med Hyg. 1970;19(1):110-8. doi:10.4269/ajtmh.1970.19.110.
128. Brandt WE, McCown JM, Gentry MK, Russell PK. Infection enhancement of dengue type 2 virus in the U-937 human monocyte cell line by antibodies to flavivirus cross-reactive determinants. Infect Immun. 1982;36(3):1036-41. doi:10.1126/science.aal4365.
129. Fagbami AH, Halstead SB, Marchette NJ, Larsen K. Cross-infection enhancement among African flaviviruses by immune mouse ascitic fluids. Cytobios. 1987;49:49-55.
130. Bardina SV, Bunduc P, Tripathi S, Duehr J, Frere JJ, Brown JA, Nachbagauer R, Foster GA, Krysztof D, Tortorella D, et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science. 2017;356(6334):175-80. doi:10.1126/science. aal4365.
131. Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, Sakuntabhai A, Cao-Lormeau VM, Malasit P, Rey FA, et al. Dengue virus sero-cross-reactivity drives antibody dependent enhancement of infection with Zika virus. Nat Immunol. 2016;17(9):1102-8. doi:10.1038/ni.3515.
132. Paul LM, Carlin ER, Jenkins MM, Tan AL, Barcellona CM, Nicholson CO, Michael SF, Isern S. Dengue virus antibodies enhance Zika virus infection. Clin Transl Immunology. 2016;5(12):e117. doi:10.1038/cti.2016.72.
133. Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney MC, Medits I, Sharma A, Simon-Lorière E, Sakuntabhai A, Cao-Lormeau VM, Haouz A, et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. 2016;536(14):48-53. doi:10.1038/ nature18938.
134. Robbiani DF, Bozzacco L, Keefe JR, Khouri R, Olsen PC, Gazumyan A, Schaefer-Babajew D, Avila-Rios S, Nogueira L, Patel R, et al. Recurrent potent human neutralizing antibodies to Zika virus in Brazil and Mexico. Cell. 2017;169:597-609. doi:10.1016/j. cell.2017.04.024.
135. CollinsMH,McGowan E, Jadi R, Young E, Lopez CA, Baric RS, Lazear HM, de Silva AM. Lack of durable cross-neutralizing antibodies against Zika virus from dengue virus infection. Emerg Infect Dis. 2017;23(5):773-81. doi:10.3201/eid2305.161630.
136. Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S, Vanzetta F, Minola A, Jaconi S, Mele F, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016;353(6301):823-6. doi:10.1126/science. aaf8505.
137. Halai UA, Nielsen-Saines K, Moreira ME, Sequeira PC, Junior P, Zin AA, Cherry JD, Gabaglia CR, Gaw SL, Adachi K, et al. Maternal Zika virus disease severity, virus loadm prior dengue antibodies and their relationship to birth outcomes. Clin Infect Dis. 2017;65(6):877-83. doi:10.1093/cid/cix472.
138. Kennedy RB. Pushing forward with Zika vaccines. EBioMedicine. 2016;13:29-30. doi:10.1016/j.ebiom.2016.10.016.
139. World Health Organization. Current Zika product pipeline. Current Zika product pipeline. Geneva (SW): World Health Organization; 2016 [accessed 2016 Sep 18]. http://www.who.int/blueprint/ priority-diseases/key-action/zika-rd-pipeline.pdf
140. Abbink P, Larocca RA, De La Barrera RA, Bricault CA, Moseley ET, Boyd M, Kirilova M, Li Z, Ng’ang’a D, Nanayakkara O, et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science. 2016;353(6304):1129-33. doi:10.1126/science.aah6157.
141. Dowd KA, Ko S-Y, Morabito KM, Yang ES, Pelc RS, DeMaso CR, Castilho LR, Abbink P, Boyd M, Nityanandam R, et al. Rapid development of a DNA vaccine for Zika virus. Science. 2016;354(6309):237-40. doi:10.1126/science.aai9137.
142. Kim E, Erdos G, Huang S, Kenniston T, Falo LD, Gambotto A. Preventive vaccines for Zika virus outbreak: Preliminary evaluation. EBioMedicine. 2016;13:315-20. doi:10.1016/j.ebiom.2016.09.028.
143. Larocca RA, Abbink P, Peron JPS, de A. Zanotto PM, Iampietro MJ, Badamchi-Zadeh A, Boyd M, Ng’ang’a D, Kirilova M, Nityanandam R, et al. Vaccine protection against Zika virus from Brazil. Nature. 2016;536(7617):474-8. doi:10.1038/nature18952.
144. Muthumani K, Griffin BD, Agarwal S, Kudchodkar S, Reuschel EL, Choi H, Kraynyak K, Duperret EK, Keaton AA, Chung C. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunization with a prMEnv DNA vaccine. NPJ Vaccines. 2016;1:16021. doi:10.1038/npjvaccines.2016.21
145. Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2016;543(7644):248-51. doi:10.1038/nature21428
146. Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, et al. Modified mRNA vaccines protect against Zika virus infection. Cell. 2017;168(6):1114-25. doi:10.1016/j.cell.2017.02.017.
147. Shan C, Muruato AE, Nunes BTD, Luo H, Xie X, Medeiros DBA, Wakamiya M, Tesh RB, Barrett AD, Wang T, et al. A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. Nat Med. 2017;23(6):763-7. doi:10.1038/nm.4322.
148. Halstead SB, O’Rourke EJ, Allison AC. Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes in supporting in vitro infection. J Exp Med. 1977;146:218-29. doi:10.1084/jem.146.1.218.
149. Senaratne T, Wimalaratne H, Alahakoon DGS, Gunawardane N, Carr J, Noordeen F. Characterization of dengue virus infections in a sample of patients suggests unique clinical, immunological, and virological profiles that impact on the diagnosis of dengue and dengue hemorrhagic fever. J Med Virol. 2016;88(10):1703-10. doi:10.1002/jmv.24525.
150. Barcellos C, Xavier DR, Pavão AL, Boccolini CS, Pina FM, Romero R, Pedroso M, Romero D, Romão AR. Increased hospitalizations for neuropathies as indicators of Zika virus infection, according to Health Information System data, Brazil. Emerg Infect Dis. 2016;22(11):1994-1899. doi:10.3201/eid2211.160901
151. dos Santos T, Rodriguez A, Almiron M, Sanhueza A, Ramon P, de Oliveira WK, Coelho GE, Badaró R, Cortez J, Ospina M, et al. Zika virus and the Guillain-Barré Syndrome - Case series from seven countries. N Engl J Med. 2016;375(16):1598-601. doi:10.1056/ NEJMc1609015.
152. Oehler E, Watrin L, Larre P, Leparc Goffart I, Lastere S, Valour F, Baudouin L, Mallet H, Musso D, Ghawche F. Zika virus infection complicated by Guillain-Barre syndrome - case report, French Polynesia, December 2013. Euro Surveill. 2014;19(9):20720. doi:10.2807/1560-7917.ES2014.19.9.20720.
153. de Oliveira WK, Carmo EH, Henriques CM, Coelho G, Vazquez E, Cortez-Escalante J, Molina J, Aldighieri S, Espinal MA, Dye C. Zika virus infection and associated neurologic disorders in Brazil. N Engl J Med. 2017;376(16):1591-3. doi:10.1056/ NEJMc1608612.
154. Maslow JN. Vaccine development for emerging virulent infectious diseases. Vaccine. 2017;35:5437-43. doi: 10.1016/j. vaccine.2017.02.015.
155. European Centre for Disease Prevention and Control. Epidemiological update: Additional confirmed cases of Middle East respiratory syndrome coronavirus (novel coronavirus) in France, Saudi Arabia, and Tunisia. In. Stockholm (Sweden): European Centre for Disease Prevention and Control; 2013
156. World Health Organization. Global alert and response (GAR): Novel coronavirus infection-update (Middle East respiratory syndrome coronavirus). In. Geneva (Switzerland): World Health Organization; 2013. Available at http://www.who.int/csr/don/2013_05_23_ncov/en/
157. European Centre for Disease Prevention and Control. Updated rapid risk assessment: Severe respiratory disease associated with Middle East respiratory syndrome coronavirus (MERS-CoV). In. Stockholm (Sweden): European Centre for Disease Prevention and Control; 2013
158. Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, Funkhouser W, Gralinski L, Totura A, Heise M, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection inmice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85(23):12201-15. doi:10.1128/JVI.06048-11.